ERBB2 and breast carcinoma: Furthermore, there is increasing interest in the analysis and targeted treatment of HER2-low breast cancers that express HER2 (HER2 immunohistochemistry 1+ or 2+, but FISH negative) because of the apparent success of HER2-targeted treatment for HER2-low breast cancers [25].